Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843349 · ClinicalTrials.gov registry record · NA
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
A NA study of Kidney Disease, sponsored by Myles Wolf.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT00843349 is a NA study of Kidney Disease that has completed, run by Myles Wolf. The registered enrollment target is 43 participants, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00843349, a NA study of Kidney Disease, has completed, sponsored by Myles Wolf.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease (CKD). More specifically, the goals of the research are (1) to understand the cause of hyperparathyroidism - a hormone problem that often develops in patients who have kidney disease and (2) to test whether decreasing phosphorus intake could help improve or prevent hyperparathyroidism.
Conditions Studied
Interventions
- DRUG Lanthanum Carbonate
- OTHER 900 mg Phosphate Diet
- DRUG LC Placebo
- OTHER Ad Libitum Diet
Study Locations (1)
Florida
- University of Miami Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00843349
The ClinicalTrials.gov registry entry for NCT00843349 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower). The listed sponsor is Myles Wolf, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Lanthanum Carbonate is the first listed.
NCT00843349 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00843349 about?
NCT00843349 is a clinical study titled "Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)". The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease (CKD). More specifically, the goals of the research are (1) to understand the cause of hyperparathyroidism - a hormone problem that often deve...
What is the current status of trial NCT00843349?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2009-07. Estimated completion is 2012-03.
What conditions does trial NCT00843349 study?
This clinical trial studies the following conditions: Kidney Disease.
What interventions are being tested in trial NCT00843349?
The interventions under investigation include: Lanthanum Carbonate (DRUG), 900 mg Phosphate Diet (OTHER), LC Placebo (DRUG), Ad Libitum Diet (OTHER).
Who is sponsoring clinical trial NCT00843349?
This trial is sponsored by Myles Wolf, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00843349 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
RECRUITING · NA
-
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
COMPLETED · NA
-
Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research
COMPLETED · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.